Release Date: 23-Jan-2025
6MW3211 is a promising humanized bispecific antibody developed by Mabwell (Shanghai) Bioscience, with a focus on cancer immunotherapy. This innovative treatment is designed to target two key immune checkpoints, PD-L1 and CD47, which play significant roles in helping tumors evade immune surveillance. By selectively binding to both PD-L1 on tumor cells and CD47, 6MW3211 aims to attenuate the CD47-SIRPandalpha; signaling pathway, which is a critical mechanism that tumors use to avoid phagocytosis. Additionally, the antibody blocks the PD-1/PD-L1 checkpoint, which is another way tumors suppress immune responses, particularly the activation of T cells. By disrupting these two pathways, 6MW3211 enhances both the phagocytosis of tumor cells and T cell activation, potentially leading to stronger immune responses against the cancer.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
Mabwell has leveraged its internal bispecific and bifunctional antibody development platform to create 6MW3211, incorporating an IgG-like structure with a common light chain. This design aims to address the common challenges of bispecific antibody production, such as pairing issues, while simplifying the manufacturing process. The structure also enables efficient binding to both targets, which is crucial for its therapeutic activity. One of the key advantages of 6MW3211 is its selectivity. While it binds to CD47 on tumor cells, it does not bind to human or monkey erythrocytes, suggesting a favorable safety profile, particularly in terms of avoiding unwanted interactions with red blood cells.
Currently, 6MW3211 is undergoing clinical development in both China and the United States. The drug is in Phase 2 clinical trials, where it is being evaluated for its efficacy in treating various cancers. As a Class I drug candidate, it represents an exciting advancement in the field of cancer immunotherapy, particularly in the way it targets and modulates two critical immune checkpoints simultaneously. If successful, 6MW3211 could provide a new, more effective treatment option for patients with cancers that are resistant to current therapies.